Cancer Clinical Trials

Breast

  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • ECOG 2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

  • Novartis CLEE011G2301 - A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy As An Adjuvant Treatment In Patients With Hormone Receptor-Positive, HER2-Negative, High Risk Early Breast Cancer

  • NRG NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

  • Puma Puma-NER-6201 - An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

  • RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Digestive/Gastrointenstinal

  • Halozyme HALO-109-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Genetics

  • ECOG-ACRIN EAY-131 - A Trial That Aims to Establish Whether Patients With Tumor Mutations, Amplifications Or Translocations in One of the Genetic Pathways of Interest Are Likely to Derive Clinical Benefit If Treated With Agents Targeting That Specific Pathway In A Single-Arm Design

Gynecologic

  • GOG 0225 - Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?

  • Tesaro PR-30-5017-C - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Hematologic/Blood

  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Respiratory/Thoracic

  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • Oncocyte PRO068 - A Study to Evaluate a Panel of Blood Biomarkers For Use In Patients Undergoing Evaluation For Lung Cancer, ONC-LN-04

  • SWOG S1400 - Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP)

  • Wistar Institute 20171814 - Identification of Cancer Markers in Samples of Peripheral Blood

Skin

  • ECOG-ACRIN EA6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma